Robert Joseph Cobuzzi Jr. - 01 Nov 2021 Form 4/A - Amendment Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)

Role
President & CEO, Director
Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
Issuer symbol
CRVO
Transactions as of
01 Nov 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
02 Feb 2022, 19:18:58 UTC
Date Of Original Report
03 Nov 2021
Next filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DFFN Common Stock Options Exercise +16,350 +117% 30,350 01 Nov 2021 Direct F1
transaction DFFN Common Stock Disposed to Issuer -6,049 -20% 24,301 01 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Restricted Stock Unit Options Exercise $0 -16,350 -17% $0.000000 81,750 01 Nov 2021 Common Stock 16,350 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 1, 2021 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 10,301 Shares and (ii) $2,722.05 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $0.45. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer.

Remarks:

This Form 4/A amends and restates the original Form 4 filed on November 3, 2021 (the "Original Form 4") to reflect (i) the hybrid settlement of the portion of the restricted stock unit award vested on the Vesting Date, rather than the all-share settlement of such portion inadvertently reported in the Original Form 4, and (ii) the Reporting Person's previously reported new address.